Company ProfilePremium

Ramsay Health Care Limited

Company Profile Analysis

Ticker: RHC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ramsay Health Care Limited - Company showcase

Year Founded & Workforce

1964

92,400 Employees

Ramsay Health Care Limited logo

Ramsay Health Care Limited Employee Contacts

70 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Ramsay Health Care Limited Overview

FY22–FY24 figures are company statements of "over" 86,000 / 89,000 / 90,000 [S6][S5][S4]; FY26 is the analyst sum of divisional disclosures [S2]; a group-wide FY25 figure was not located.

Ramsay Health Care is Australia's largest private hospital operator and one of the world's larger listed private hospital groups, built over six decades on the founding ethos of "people caring for people." Its strategic centre of gravity is a 70-facility Australian network (including the managed Joondalup and Noosa public campuses) that admitted 1.24 million patients in FY26 and generated 55% of group underlying EBIT. Around this core sit two UK businesses — an NHS-dependent acute hospital chain (34 hospitals) and Elysium, a specialist mental health provider in turnaround — and a 52.79% controlling stake in Ramsay Santé, the Paris-listed European private hospital and primary care leader. Under CEO Natalie Davis (ex-Woolworths, ex-McKinsey), the company is pivoting from a diversified international holding structure to a focused, capital-disciplined Australian acute-care platform: closing sub-scale sites, lifting theatre utilisation, negotiating indexation-linked insurer contracts, acquiring selectively (National Capital Private Hospital, Canberra) and proposing to demerge Ramsay Santé by December 2026.


Company's own description (latest annual report)

In its FY26 Operating and Financial Review, Ramsay describes itself as a provider of quality healthcare services in a core Australian market, a UK presence comprising two businesses (Ramsay UK hospitals and Elysium mental health services), and a European presence through its 52.79% ownership of Ramsay Santé in France and the Nordics [S2]. The stated Australian vision is to be "Australia's most trusted leading healthcare provider" [S2]. Ramsay Australia's focus is described as operating private acute hospitals delivering complex care in priority therapeutic areas — cardiology, oncology, orthopaedics and psychology (mental health) — alongside mental health facilities, two managed public hospitals, hospital-in-the-home, telehealth, 31 allied health clinics and the Ramsay Pharmacy franchise network supporting 62 community pharmacies and 41 in-hospital dispensaries [S2].

Independent characterisation

Ramsay is an asset-heavy, labour-intensive healthcare services operator whose economics are governed by three variables: (i) activity and acuity (admissions, theatre utilisation, case mix), (ii) price indexation set by private health insurers (Australia), the NHS tariff (UK), local authorities and NHS commissioners (Elysium) and the French state (Santé), and (iii) labour cost inflation — employee and contractor costs consumed 57.2% of FY26 group revenue (A$10,703.0m of A$18,706.9m) [S2]. Ramsay has no product IP, no subscription base and no manufacturing; it monetises clinical capacity (beds, theatres, cath labs) staffed by employed nurses and allied health professionals and used by independent visiting medical officers (VMOs) who bring patients. Competitive advantage stems from network scale with insurers, owned freehold real estate (44 owned Australian facilities generated A$808.6m of EBITDAR in FY26 before overhead allocation [S3]), doctor relationships, and clinical reputation. The structural vulnerability is that Ramsay is a price-taker in most markets: payors' indexation has lagged cost inflation since 2021 in every geography, which is why margins have compressed from pre-COVID levels and why the current strategy prioritises utilisation, procurement and portfolio pruning rather than greenfield expansion.

Revenue model and mix (FY26)

Revenue type, FY26AUD Mn% of revenue from contractsSource
Revenue from patients17,987.996.8[S2]
Revenue from ancillary services472.12.5[S2]
Rental revenue (e.g., medical suites)117.80.6[S2]
Revenue from contracts with customers18,577.8100.0[S2]

The model is overwhelmingly fee-for-service (episode-based or per-diem reimbursement). There is no subscription or licensing revenue. Within Australia, FY26 revenue comprised revenue from customers (hospital admissions and outpatients) A$5,254.1m, pharmacy A$626.3m and other (mainly prostheses and rental) A$913.2m [S2].

Value chain position and customers

Ramsay sits at the provider layer between payors and patients. Payor types: private health insurers (Australia; UK private medical insurers such as Bupa and VitalityHealth), governments and public health systems (WA Government at Joondalup; NHS England via e-referral and commissioning; local authorities for Elysium placements; French national health insurance; Swedish regions such as Region Stockholm at St Göran), self-pay patients, and the Department of Veterans' Affairs in Australia [S2][S3][S21]. End-markets: acute surgical and medical care, maternity, rehabilitation, inpatient mental health, secure and complex mental health care (UK), primary care and imaging (Europe), and retail/hospital pharmacy (Australia).

Payor mix indicators (FY26): In Australia, privately funded admissions grew 2.8% and publicly funded admissions (including public-in-private) grew 9.5% on a like-for-like basis [S2]. In Ramsay UK, NHS admissions were 72.6% of total admissions (74.8% in FY25), with private pay (insured plus self-pay) at 27.4% [S3][S2].

Strategy

Stated strategy (FY26 Annual Results / OFR)

Management frames its agenda around three CEO priorities [S3]:

  1. Transform the market-leading Australian hospital business — under the "Ramsay 2030" strategy refreshed after Davis's arrival.

  2. Strengthen capital discipline and improve capital returns across the portfolio — including the Ramsay Santé separation.

  3. Evolve the culture of "people caring for people" to innovate and accelerate delivery.

Priority therapeutic areas (Australia): cardiology, orthopaedics and cancer care, with mental health retained as a core service line [S1][S2].

The "Big 5" Australian hospital operations initiatives [S3]

InitiativeFY26 progressFY27 plan
GrowthAdmitting VMOs +3.3%; theatre utilisation ~+90bps to 70% while adding 22 rooms; catchment-based data insights; CRM; GP liaison and business development sales force uplift; higher robotics useCatchment growth plans; ramp-up of new developments; National Capital integration
ProcurementBenefits ahead of target; supplies as % of revenue down ~50bps"Switch and Save" data tool; food menu standardisation; rapid tendering of non-clinical categories
Revenue cycle managementStrong cash collection; cash conversion cycle -4 daysAdmission digitisation; coding standardisation; claims generation efficiencies; upgraded Patient Administration System
WorkforceRecord graduate intakes; national hiring to reduce agencyAgency reduction; skill mix; EBA negotiations; future rostering model
Technology and AIRollout of key hospital systems; pilot AI use casesSmart Rostering and team app; procedural profitability analytics; contract management; prostheses tracking; AI use cases

Strategic initiatives — last 24 months

InitiativeDateDetailSource
Ramsay Santé strategic review and proposed demergerFeb 2025 (review) → Feb 2026 (proposal) → Nov 2026 (vote)In-specie distribution of 52.79% stake; Santé CDIs to trade on ASX; shareholders' agreement with Crédit Agricole Assurances terminated effective 1 Oct 2026[S9][S8]
National Capital Private HospitalDec 2025 – Sep 2026A$251m debt-funded entry into ACT; expected top-20 hospital by revenue and profit; EPS-accretive in year one[S12][S13]
Portfolio optimisationFY264 Australian sites closed, surplus land for sale; Elysium 7 sites closed[S3]
Payor model reformFY25–FY26All major PHI negotiations completed with improved FY25–26 indexation; new multi-year partnership with a major insurer; four agreements with indexation linked to sector metrics[S7][S3]
Bupa partnership expansionMay 2025Out-of-hospital pilots (home/virtual rehab, community mental health follow-up)[S21]
Clinical trials networkFY26Ramsay Research and Development Network expanded to 22 sites; trials +28%[S3]
Elysium turnaroundFY25–FY27Strategic diagnostic with external advisers (2025); three phases of central cost reduction (161 FTE); fee negotiation; site divestments[S2]
Executive capability rebuild2,025New CFO, COO Australia, CCO Australia, Technology & Digital, Health & Strategy executives[S15][S14b]
Office consolidationFY26Global and Australian support offices merged at St Leonards[S1]
Sustainability resetAug 2026Net zero (Scope 1+2) moved from 2040 to 2050; UK and Elysium Scope 3 net zero by 2050[S1]
Investor Day30 Nov 2026 (scheduled)Group Executive to present progress and plans post-demerger vote[S3]

Medium-term targets and FY27 guidance

ItemGuidance / targetSource
Funding Group EBITGrowth and EBIT margin improvement in FY27[S1]
AustraliaIncremental YoY EBIT growth (incl. and excl. National Capital) and margin expansion; includes A$10–15m higher IT/technology/transformation opex[S1]
National CapitalEPS-accretive in first 12 months; transition opex A$9–11m (excluded from underlying, skewed to 1H)[S1]
UK Hospitals / ElysiumEBIT growth in FY27 for both; Elysium plans for continued weak demand[S1]
Funding Group net financing expense (incl. AASB 16)A$280–300m[S1]
Funding Group underlying effective tax rate~30%[S1]
Funding Group capexA$480–520m (Australia A$380–410m incl. A$6–10m National Capital)[S1][S2]
Dividend payout60–70% of underlying group NPAT after NCI[S1]
LeverageFunding Group <2.5x (covenant 3.5x, or 4.0x if investment grade)[S3]
Ramsay Santé (standalone)"Connecting Care 2030" — five strategic pillars; solid organic growth targeted[S11]

Products & Services

Ramsay sells clinical services rather than products; the "catalog" below lists each service line and named flagship facilities. Pricing is set by payor contracts rather than list prices unless otherwise noted.

Australia

OfferingDescription and capabilityTarget customer / payorLatest developmentPricing model
Acute private hospitalsFull-service surgical and medical hospitals with ICU/CCU, cath labs, emergency departments at selected sites. Flagships (licensed beds / theatres, procedure rooms and cath labs): Hollywood Private, Perth (950 / 30); Greenslopes Private, Brisbane (700 / 36); John Flynn Private, Gold Coast (358 / 18); North Shore Private, Sydney (351 / 27); Peninsula Private, Victoria (350 / 13); Pindara Private, Gold Coast (323 / 19); St George Private, Sydney (276 / 20); Warringal Private, Melbourne (252 / 19); Westmead Private, Sydney (216 / 17) [S3]Privately insured patients; VMOs; DVA; public-in-privateWarringal ED opened 12 Aug 2026; Hollywood adding 2 theatres and 2 cath labs by Dec 2026; St George 2 cath labs due Q4 FY27 [S3]Insurer Hospital Purchaser Provider Agreements (episode/per-diem) with annual indexation; four agreements now link indexation to sector metrics [S3]
Public-private campusesJoondalup Health Campus, WA (796 beds / 25 rooms, public + private) operated under contract with WA Government; Noosa Hospital, QLD (public, 92 beds) [S3]State governmentsNew Joondalup funding mechanism (March 2024) reduced FY26 EBIT by a net A$26m [S2]Government activity-based/contracted funding
Day surgery and short-stay surgical centresRamsay Surgical Centres (Cairns, Miranda, Orange, Coffs Harbour, Charlestown, Cleveland), Short Street Day Surgery, Pindara Day Procedure Centre, Victorian Day Procedure Centre [S3]PHI and self-funded day patientsCharlestown (6 rooms) and Caloundra opened FY26; Cleveland (3 theatres) opened Aug 2026; Campbelltown centre commencing [S3]Episode-based PHI contracts
Emergency departmentsSeven private EDs plus Joondalup and Noosa public EDs; EDs drive c.20% of overnight inpatient admissions [S3][S4]Walk-in and referred patientsWarringal ED opened Aug 2026 [S3]Patient fees plus downstream admissions
Mental health (inpatient and day)Ramsay Clinics (e.g., New Farm 114 beds, Albert Road 123, Northside 137, Adelaide 91, Wentworthville, Macarthur, Cremorne, Cairns, Caloundra) [S3]PHI members (gold-tier cover), DVAFY26 mental health admissions -3.9% (day programs down; overnight +0.9%) as insured members down-tier from gold to silver [S3]Per-diem PHI contracts
Rehabilitation hospitalsDonvale (85 beds), Mt Wilga (119), plus rehab wards across networkPHI, DVA, workers' compensationRehab admissions +3.8% FY26 [S2]Per-diem
Maternitye.g., Frances Perry House (Melbourne); remote foetal monitoring deployed at all maternity sites [S3]PHI membersFlat maternity admissions FY26 [S2]Episode-based
Oncology and infusionWestern Sydney Private Oncology and Infusion Centre; cancer care is a priority therapeutic areaPHIExpanded service differentiation targeted [S2]Episode/day fees
Hospital-in-the-home and telehealthOut-of-hospital acute and post-acute carePHI (incl. Bupa pilots)Bupa agreement (May 2025) pilots home/virtual rehab and community mental health follow-up [S21]Contracted packages
Allied health clinics31 clinics (physiotherapy etc.) [S2]Patients, PHI extras—Fee-for-service
Ramsay PsychologyCommunity psychology practices (14 in FY24)Medicare/self-payMajority of clinics closed in FY25 with A$16.3m impairment [S2][S4]Fee-for-service
Ramsay PharmacyFranchise network supporting 62 community pharmacies and 41 in-hospital dispensariesRetail customers; hospital patientsRevenue A$626.3m FY26, +5.7% [S2]Retail/PBS dispensing; franchise fees
Ramsay Research and Development NetworkNational clinical trials capability across 22 sitesSponsors, patients, cliniciansTrials activity +28% FY26 [S3]Sponsor-funded
National Capital Private Hospital (Canberra)148 beds, 8 theatres, 1 cath lab, ICU/CCU; co-located with Canberra Hospital, adjacent to ANU Medical School; lease to 2064PHI, ACT catchmentAcquired 1 Sep 2026 for A$251m [S13][S12b]PHI contracts
Patient amenities"At Your Request" hospital dining being scaled nationally [S3]InpatientsRollout FY26–FY27Included in episode

United Kingdom — Ramsay UK

OfferingDescriptionCustomerLatest developmentPricing
Acute independent hospitals and day procedure centres (34)Orthopaedics, spinal, ophthalmology, general surgery, cancer care, diagnostics, physiotherapyNHS e-referral patients (72.6% of admissions), PMI, self-payAverage revenue per admission +6.7% FY26 on acuity and mix [S2]; Glendon Wood (Northamptonshire) opened Aug 2023; West Valley (Croydon) closed Jan 2024 [S4]NHS national tariff (FY26/27 revised to 1.24%); PMI multi-year contracts; self-pay packages
Insurer partnership networksHip, knee, spinal and ophthalmic partnership networks with VitalityHealth; Bupa specialist cancer care centres (breast, bowel, prostate)PMI membersVitalityHealth long-term agreement extended (Sep 2026); Bupa UK four-year contract [S21]Negotiated network tariffs
Diagnostic imagingImaging service within networkNHS, PMIData centres written down FY24 [S4]Fee-for-service

United Kingdom — Elysium Healthcare

OfferingDescriptionCustomerLatest developmentPricing
Secure mental health hospitalsMedium- and low-secure inpatient servicesNHS England commissionersOccupancy 86.1% FY26; June 2026 occupancy 87.2% [S3]Per-bed daily fee; NHS tariff awards and spot negotiations; average daily fee +4.4% FY26 [S2]
Neurological rehabilitation and complex careNeuro-rehab, complex care homes, learning disability and autism servicesNHS, local authoritiesWeak local authority demand; shift to community settings [S3]Daily fees
Enhanced packages of care / complex recoveryHigher-acuity placements targeted for growthNHS, local authoritiesConversion focus in FY27 [S2]Premium daily fees
Educational settingsResidential and educational placements (per company description)Local authorities—Placement fees
Portfolio88 sites, c.2,196 beds; 7 sites closed and 239 beds removed in FY26; 5 sites held for sale—Turnaround under CEO Joe O'Connor (from Jan 2026) [S2][S3]—

Europe — Ramsay Santé (52.79% owned; proposed for demerger)

OfferingDescriptionCustomerLatest developmentPricing
France — MSO acute careMedicine, surgery, obstetrics; c.150 hospitals historicallyFrench national health insurance; complementary insurersMSO admissions +2.5% FY26; targeted maternity closures [S2][S3]Regulated DRG tariffs (0.5% for 2025, 0% for 2026) less 0.7% prudential coefficient withheld [S2]
France — follow-up care and rehabilitation (FCR/SMR) and mental healthPost-acute and psychiatric facilitiesNational health insuranceAllocation-based funding model [S4]Regulated
Imaging and radiotherapy11 new imaging equipment sites installed FY26Patients, referrersStrategic higher-margin value pool [S2]Regulated fees
Primary care (France)Cosem medical centres (12 acquired June 2024)PatientsIntegration into care pathways [S4]Regulated fees
Nordics — Capio (Sweden, Norway, Denmark)Primary care (Proximity Care), specialist clinics, orthopaedics, elderly care, St Göran acute hospital (Stockholm)Regional governments, insurersSt Göran 8+4-year contract from 5 Jan 2026 on improved terms; €26m refundable deposit paid [S2][S3]Regional contracts
Italy93-bed hospitalItalian payors——
Scale487 facilities in 5 countries; 40,000+ employees; 13m patients per year [S2]—"Connecting Care 2030" strategy (Sep 2026) [S11]—

Financial Narrative

Basis of preparation: FY22 figures are as originally reported (Ramsay Sime Darby equity-accounted within continuing operations) [S6]; FY23 figures are as restated in the FY24 Appendix 4E with RSD treated as discontinued [S4]; FY24 from FY24 Appendix 4E [S4]; FY25–FY26 from FY26 Appendix 4E [S2]. "Underlying" figures exclude items the company classifies as non-recurring (impairments, restructuring, transaction costs, asset-sale gains). All values A$m unless stated.

Income statement

Notes: Gross profit is not a reported metric for Ramsay; the proxy deducts "medical consumables and supplies" from total revenue and other income (including interest income) and is an analyst construct. FY22 underlying EBIT = reported EBIT A$891.3m plus A$60.1m negative non-recurring items [S6] and includes Ramsay's share of RSD profit (A$15.3m). FY23 underlying EBIT = A$1,001.4m less A$42.1m positive non-recurring items [S4]. FY24 statutory NPAT includes the A$618.1m RSD sale profit [S4]. FY25 statutory NPAT includes a A$291m post-tax UK impairment [S2].

Margins and growth

Analyst calculations on total revenue and other income less interest income (margins) and total revenue including interest (employee cost ratio) from [S2][S4]. Revenue CAGR FY22–FY26: 8.0% p.a. (reported A$); FY23–FY26: 6.8% p.a. FY26 constant-currency revenue growth was 4.2% [S2].

Commentary — income statement. The five-year arc has three phases. FY22–FY23 (COVID hangover and acquisition-led growth): revenue rose 11.6% in FY23 largely from full-year contributions of Elysium and GHP (A$767m) [S5], but margin recovery was choked by labour shortages, agency usage and inflation, while net financing costs (excluding AASB 16) doubled as base rates rose [S5]. FY24–FY25 (margin trough and write-downs): underlying EBIT edged up, but Ramsay Santé's EBIT fell 33% in local currency as French tariffs (0.3% initial 2024 indexation) and withdrawn COVID support eroded margins [S4], and Elysium's deterioration forced the A$305m UK impairment in 1H FY25 [S2]. Statutory NPAT swung from A$888.7m (RSD gain) to A$24.0m. FY26 (inflection): underlying EBIT rose 11.8% cc and underlying NPAT 22.9% cc, the first year in which all regions grew EBIT [S1]. The drivers were Australian indexation finally exceeding cost inflation, +90bps theatre utilisation, ~50bps procurement savings on supplies, Elysium cost-outs and the St Göran contract [S3]. Underlying EBIT margin (6.2%) is nonetheless still below FY22's 6.9% and well below pre-COVID levels; the operating leverage case remains a work in progress. The underlying effective tax rate rose to 35.9% (32.7% FY25) because Ramsay Santé is loss-making before tax yet pays French CVAE [S2], a drag that disappears on demerger (Funding Group rate ~29–30%).

Balance sheet

Sources: [S2][S4]; FY22 balance items from the FY24 Appendix 4E reconciliation of financing liabilities and statement of changes in equity (opening 1 July 2022 balances) [S4]. Net debt excluding leases for FY22–FY24 is an analyst calculation (borrowings less cash); FY23–FY24 company-reported net debt including derivatives was A$5,147.2m and A$4,376.1m [S4]. Goodwill is not separately disclosed in the reviewed summaries; intangibles are predominantly goodwill (the UK goodwill write-down of A$248.4m in FY25 [S2]).

Commentary — balance sheet. The defining feature is the dual-balance-sheet structure: Ramsay Santé carries non-recourse secured debt of roughly €1.6bn (bank net debt, IAS 17 basis) at 4.7x leverage, while the Funding Group carries A$1.9bn of net debt at 1.83x [S3]. Consolidated net debt including leases of A$10.3bn therefore overstates the risk to Ramsay shareholders; roughly 55% of consolidated lease liabilities (A$3.49bn) and 58% of net bank debt (A$2.65bn) sit inside Ramsay Santé [S3]. The RSD sale in December 2023 cut Funding Group leverage from 3.22x to 2.00x [S4]. In FY26 a ~A$300m adverse currency translation and the Elysium portfolio restructure (A$300m reduction in right-of-use assets and leases) shrank the balance sheet [S2]. Negative working capital is structural for a hospital operator (creditors and employee provisions exceed receivables). Net tangible assets are negative (–A$2.9 per share including right-of-use assets) [S2].

Cash flow

Sources [S2][S4]. FY22 OCF is derived from the FY23 disclosure that OCF rose 78.8% to A$1,279.6m [S5]. No on-market buybacks occurred FY23–FY26 per statements of changes in equity [S2][S4].

Commentary — cash flow. The most important FY26 data point is not consolidated cash flow (down 3.4% because of the timing of French government receipts in Ramsay Santé) but the 46% jump in Funding Group operating cash flow to A$869.1m and the near-sevenfold rise in Funding Group free cash flow to A$382.4m [S2]. That reflects revenue-cycle discipline (Australian cash conversion cycle shortened by 4 days), capex restraint (Funding Group capex down 9% to A$487.9m cc) and the absence of the prior year's tax on the RSD gain [S3]. On a consolidated basis, after lease principal (a real economic cost under AASB 16), free cash flow was only A$104m in FY26 — less than half the dividend — underscoring why separating the cash-consuming Ramsay Santé structure flatters the remaining group's cash profile.

Returns, leverage and efficiency ratios

Notes: Company-reported ratios from [S2][S3][S4]; others are analyst calculations. Payout ratios: FY22 analyst (DPS/diluted EPS); FY23 on statutory NPAT; FY24 on continuing basic EPS; FY25 on underlying continuing NPAT; FY26 on underlying NPAT [S5][S4][S7][S2]. FY23 tax rate shown on restated continuing basis (34.4%); FY23 as originally reported was 33.2% [S5][S4] — source discrepancy noted. A formal cash conversion cycle is not disclosed; the company states only that Australia's cycle improved 4 days in FY26 [S3]; receivables days are an analyst proxy.

Commentary — ratios. Return metrics are low in absolute terms (accounting ROIC 4.6%) because of the large goodwill and lease base, but the Funding Group's ROCE of 14.8% (up 150bps) demonstrates that the Australia/UK perimeter earns comfortably above its cost of capital on tangible capital [S2]. Reported interest coverage of 1.8x looks thin only because consolidated finance costs include A$290m of lease interest and Ramsay Santé's high-cost secured debt; the covenant interest cover of 8.94x is the relevant solvency test. The step-change in receivables days (55 to 45) reflects collection focus and the Ramsay Santé timing of French government payments, and supports management's revenue-cycle narrative.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey operating facts (FY26)

Australia

70 hospitals, clinics and day surgery units incl. managed Joondalup and Noosa public campuses; mental health clinics; 31 allied health clinics; hospital-in-the-home; telehealth; Ramsay Pharmacy (62 community pharmacies, 41 in-hospital dispensaries); global head office

1.24m admissions; 36,000+ employees; underlying EBIT margin 9.4% [S2]

UK — Ramsay UK

34 acute hospitals and day procedure centres serving NHS, insured and self-pay patients

218,900 admissions; 7,500+ employees; underlying EBIT margin 10.2% [S3][S2]

UK — Elysium

Specialist mental health, neurological and care services across England and Wales; 88 sites, c.2,196 beds

1,981 average paid beds; 86.1% occupancy; c.8,900 employees [S2][S3]

Europe — Ramsay Santé (France)

Acute (MSO), follow-up and rehabilitation, mental health, imaging, primary care; plus a 93-bed hospital in Italy

Underlying EBIT A$206.7m, down 7.4% cc [S2]

Europe — Ramsay Santé (Nordics)

Sweden (incl. St Göran, Proximity Care primary care, orthopaedics, elderly care), Norway, Denmark

Underlying EBIT A$124.1m, up 65.6% cc [S2]

Revenue by Segment

SegmentFY2023FY2024FY2025FY2026

Australia revenue (AUD Mn)

5,711.06,061.66,322.76,818.1

UK revenue (AUD Mn)

1,941.22,360.82,661.72,605.0

of which Ramsay UK revenue (AUD Mn)

1,148.71,401.71,568.71,567.4

of which Elysium revenue (AUD Mn)

792.5959.11,093.01,037.6

France revenue (AUD Mn)

5,291.25,764.26,098.06,334.0

Nordics revenue (AUD Mn)

2,395.72,593.62,704.82,941.5

Total segment revenue (AUD Mn)

15,339.116,780.217,787.218,698.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Australia revenue growth (%)

6.14.37.8

UK revenue growth reported A$ (%)

21.612.7-2.1

France revenue growth reported A$ (%)

8.95.83.9

Nordics revenue growth reported A$ (%)

8.34.38.8

Segment share of total segment revenue (%)

Segment share of total segment revenue (%)FY2023FY2024FY2025

Australia share (%)

37.236.135.5

UK share (%)

12.714.115.0

France share (%)

34.534.434.3

Nordics share (%)

15.615.515.2

Results by Segment

Segment metric (AUD Mn)FY2023FY2024FY2025FY2026

Australia EBITDA (AUD Mn)

786.3802.4816.6892.7

UK EBITDA (AUD Mn)

206.3314.0317.2347.4

France EBITDA (AUD Mn)

751.3735.2760.0743.6

Nordics EBITDA (AUD Mn)

258.3274.1265.6324.9

Australia reported EBIT (AUD Mn)

556.5572.5560.2629.9

UK reported EBIT (AUD Mn)

63.8160.6-144.3176.9

France reported EBIT (AUD Mn)

293.7191.6218.6184.6

Nordics reported EBIT (AUD Mn)

87.472.971.7114.0

Australia underlying EBIT (AUD Mn)

542.6569.3575.5639.8

UK underlying EBIT (AUD Mn)

78.7175.4169.3191.6

Europe underlying EBIT (AUD Mn)

338.0289.3297.8330.8

Underlying EBIT margin by region (%)

Underlying EBIT margin by region (%)FY2023FY2024FY2025FY2026

Australia underlying EBIT margin (%)

9.59.49.19.4

UK underlying EBIT margin (%)

4.17.46.47.4

Europe underlying EBIT margin (%)

4.43.53.43.6

Results by Segment and Segment Margins & Growth (%)

Business unit metricFY2025FY2026

Ramsay UK underlying EBIT (AUD Mn)

147.3160.5

Elysium underlying EBIT (AUD Mn)

22.031.1

France underlying EBIT (AUD Mn)

224.0206.7

Nordics underlying EBIT (AUD Mn)

73.8124.1

Ramsay UK underlying EBIT margin (%)

9.410.2

Elysium underlying EBIT margin (%)

2.03.0

Ramsay Santé underlying loss after tax and NCI attributable to Ramsay (AUD Mn)

-39.9-34.3

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total revenue and other income less interest income (AUD Mn)

13,740.015,329.316,772.117,779.318,690.3

Revenue from contracts with customers (AUD Mn)

—14,963.916,660.217,673.818,577.8

Gross profit proxy: total revenue less medical consumables (AUD Mn)

—12,021.513,065.713,849.514,578.2

EBITDAR (AUD Mn)

—2,149.62,276.42,323.52,469.1

EBITDA reported (AUD Mn)

—2,002.22,125.72,159.42,308.6

Underlying EBITDA (AUD Mn)

———2,168.92,343.4

EBIT reported (AUD Mn)

891.31,001.4997.6706.21,105.4

Underlying EBIT (AUD Mn)

951.4959.31,034.01,042.61,162.2

Net finance costs incl. lease interest (AUD Mn)

—474.3613.0604.4591.8

Profit before tax (AUD Mn)

538.5527.1384.6101.8513.6

Income tax expense (AUD Mn)

159.3181.5121.355.5192.2

NPAT attributable to owners, statutory (AUD Mn)

274.0298.1888.724.0329.2

NPAT from continuing operations attributable (AUD Mn)

—278.2270.624.0329.2

Underlying NPAT attributable (AUD Mn)

—250.7300.1305.3364.1

Basic EPS after CARES dividend (cents)

—125.1381.63.0136.2

Diluted EPS after CARES dividend (cents)

116.1124.8380.93.0135.8

Underlying diluted EPS (cents)

———125.3151.0

Dividends per share (cents)

97.075.080.080.091.0

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY reported (%)

—11.69.46.05.1

EBITDA margin reported (%)

—13.112.712.112.4

EBIT margin reported (%)

6.56.55.94.05.9

Underlying EBIT margin (%)

6.96.36.25.96.2

Statutory net margin (%)

2.01.95.30.11.8

Underlying net margin (%)

—1.61.81.71.9

Employee and contractor costs to total revenue (%)

—57.457.557.457.2

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

—21,030.220,894.022,475.520,824.8

Cash and cash equivalents (AUD Mn)

314.2656.1662.3784.4729.9

Borrowings — current (AUD Mn)

42.869.9134.178.584.2

Borrowings — non-current (AUD Mn)

5,173.55,861.54,949.95,458.45,209.6

Total borrowings (AUD Mn)

5,216.35,931.45,084.05,536.95,293.8

Lease liabilities (AUD Mn)

5,482.45,954.95,854.16,583.05,704.7

Net debt excl. leases and derivatives (AUD Mn)

4,902.15,275.34,421.74,752.54,563.9

Net debt incl. leases, company definition (AUD Mn)

—11,102.110,230.211,335.510,268.6

Funding Group net debt excl. leases (AUD Mn)

—2,664.41,833.32,028.91,912.8

Total equity (AUD Mn)

4,526.24,823.25,527.55,708.75,593.8

Equity attributable to parent (AUD Mn)

3,933.54,154.84,897.65,023.64,956.0

Non-controlling interests (AUD Mn)

592.7668.4629.9685.1637.8

Intangible assets incl. goodwill (AUD Mn)

—6,163.76,139.96,431.15,975.5

Property, plant and equipment (AUD Mn)

—5,238.15,383.65,820.05,701.4

Right-of-use assets (AUD Mn)

—4,949.14,775.45,333.04,429.8

Total current assets (AUD Mn)

—3,895.83,872.84,040.33,704.9

Total current liabilities (AUD Mn)

—3,810.44,180.34,465.64,065.7

Working capital: current assets less current liabilities (AUD Mn)

—85.4-307.5-425.3-360.8

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

715.71,279.61,292.81,480.81,430.7

Capital expenditure (AUD Mn)

—720.9753.8776.6734.2

Free cash flow: OCF less capex (AUD Mn)

—558.7539.0704.2696.5

Lease principal repaid (AUD Mn)

—403.2450.5508.8592.1

Free cash flow after lease principal (AUD Mn)

—155.588.5195.4104.4

Dividends paid to parent shareholders (AUD Mn)

—218.7134.9161.6205.7

Dividends paid incl. non-controlling interests (AUD Mn)

—236.8158.3190.7238.0

Share buybacks (AUD Mn)

—0000

Shares issued under DRP (AUD Mn)

—18.830.439.10

Funding Group operating cash flow (AUD Mn)

———595.7869.1

Funding Group free cash flow (AUD Mn)

———58.7382.4

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE statutory on closing parent equity (%)

7.07.218.10.56.6

ROE underlying on closing parent equity (%)

—6.06.16.17.3

ROA: total NPAT on closing total assets (%)

—1.74.20.21.5

Accounting ROIC, company (%)

—4.34.34.34.6

Cash ROIC, company (%)

—10.911.711.511.9

Group ROCE, company (%)

———9.911.0

Funding Group ROCE, company (%)

———13.314.8

Current ratio (x)

—1.020.930.900.91

Borrowings to equity (x)

1.151.230.920.970.95

Borrowings plus leases to equity (x)

2.362.461.982.121.97

Net debt incl. leases to EBITDA, company (x)

—5.53.75.34.5

Net debt excl. leases to reported EBITDA (x)

—2.62.12.22.0

Funding Group covenant leverage (x)

—3.222.002.181.83

Interest coverage: EBIT over finance costs (x)

—1.91.61.11.8

Funding Group interest cover, covenant basis (x)

———8.938.94

Asset turnover: revenue over closing total assets (x)

—0.730.800.790.90

Receivables days on revenue from contracts (days)

—55.355.151.844.6

Effective tax rate reported (%)

29.634.431.554.537.4

Dividend payout ratio (%)

83.560.072.063.760.3

Revenue by Region

RegionFY2023FY2024FY2025FY2026

Australia revenue (AUD Mn)

5,711.06,061.66,322.76,818.1

United Kingdom revenue (AUD Mn)

1,941.22,360.82,661.72,605.0

France revenue (AUD Mn)

5,291.25,764.26,098.06,334.0

Nordics revenue (AUD Mn)

2,395.72,593.62,704.82,941.5

APAC total incl. Australia (AUD Mn)

5,711.06,061.66,322.76,818.1

EMEA total: UK + France + Nordics (AUD Mn)

9,628.110,718.611,464.511,880.5

Revenue by Region — UK total revenue and other income

Region (local currency)FY2023FY2024FY2025FY2026

UK total revenue and other income (GBP Mn)

1,083.01,229.01,330.71,315.8

Europe total revenue and other income (EUR Mn)

4,924.35,065.25,233.85,400.2

Europe patient revenue (EUR Mn)

4,466.44,792.14,998.55,181.0

Europe EBITDA (EUR Mn)

643.6612.4608.5624.6

UK underlying EBIT (GBP Mn)

——84.897.3

Europe underlying EBIT (EUR Mn)

——175.4195.5

Region growth

Region growthFY2024FY2025FY2026

Australia revenue growth (%)

6.14.37.8

UK revenue growth GBP (%)

13.58.3-1.1

Europe revenue growth EUR (%)

2.93.33.2

Share Price & Returns

Reference pointPrice (AUD)Source

24 Aug 2023 (post FY23 result)

48.71

[S18]

30 Aug 2024 (post FY24 result, intraday)

41.17

[S34]

Start of CY2025

34.05

[S33]

End of CY2025

34.36

[S33]

52-week low

30.39

[S18]

26 Feb 2026 (post 1H result)

42.12

[S18]

30 Jun 2026 (FY26 end)

43.98

[S33]

27 Aug 2026 (post FY26 result close)

50.06

[S18]

10 Sep 2026 (multi-year high)

54.11

[S18]

7 Oct 2026

54.55

[S18]

Return metric

Value

Basis

Year-to-date 2026

~+58%

34.43 → 54.55

1-year (approx.)

~+55%

vs ~A$35 traded in Nov 2025 [S17]

~3-year

~+12%

vs A$48.71 (Aug 2023)

5-year

Negative (exact figure n.d.)

Shares traded at ~A$80+ during the April 2022 KKR approach [S27]

FY2026 (Jul 2025–Jun 2026)

+19.4%

[S33]

Valuation Snapshot

MultipleValueBasis

Market capitalisation

A$12.6bn

230.8m shares

P/E statutory FY26

40.1x

Basic EPS 136.2c

P/E underlying FY26

36.1x

Underlying diluted EPS 151.0c

EV (ex leases)

~A$18.0bn

Mkt cap + net debt A$4,564m + NCI A$638m + CARES A$252m

EV (incl. leases)

~A$23.7bn

  • leases A$5,705m

EV/EBITDA (incl. leases, FY26 reported)

~10.3x

A$2,308.6m

EV/Sales (incl. leases)

~1.27x

A$18,690m

P/B

~2.5x

Parent equity A$4,956m

Dividend yield (fully franked)

1.7%

91c

Implied Funding Group P/E (ex-Santé stake ~A$1.1bn)

~30x

Funding Group underlying NPAT after CARES ~A$383m

Consensus forward P/E (aggregator)

~31x FY27, ~27x FY28

[S34]

Peer multiples (Spire, etc.)

n.d. in reviewed sources

—

Per-Share Data and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Interim DPS (cents)

48.550.040.040.042.5

Final DPS (cents)

48.525.040.040.048.5

Total DPS (cents)

97.075.080.080.091.0

Franking (%)

100100100100100

Final CARES dividend (A$ per CARES)

2.0553.0613.303.073.36

Group Entities

EntityAgencyRating / outlook

Ramsay Health Care (Funding Group)

Fitch

BBB- / Stable (affirmed)

Ramsay Health Care

Moody's, S&P

Not rated / n.d.

Ramsay Santé

Moody's

B1 / Negative

Ramsay Santé

S&P

B+ / Stable

Analyst Conclusions

Management guidance (FY27)

Funding Group EBIT growth and margin improvement; Australian EBIT growth with margin expansion (incl. and excl. National Capital); EBIT growth at Ramsay UK and Elysium; Funding Group net finance costs A$280–300m; underlying tax ~30%; capex A$480–520m; payout 60–70% [S1]. Ramsay Santé to be treated as discontinued in FY27 if the demerger is approved [S2].

Consensus expectations

Aggregator data imply forward P/E of ~31x FY27 and ~27x FY28, consistent with mid-teens EPS growth expectations [S34]; detailed consensus EPS/revenue for the post-demerger perimeter is n.d.

Bull case

  1. Pure-play re-rating: Removing a loss-making, 4.7x-levered subsidiary lifts group EPS (Funding Group underlying NPAT A$398m vs consolidated A$364m), lowers the tax rate to ~30% and improves ROCE optics to ~15% [S2].

  2. Operating leverage in Australia: utilisation at 70% with a 30-point spread between lowest- and top-quartile sites, plus 11 new rooms in FY27 and indexation-linked insurer contracts, can sustain double-digit EBIT growth [S3].

  3. Competitor dislocation: Healthscope's break-up and conversion to not-for-profit ownership may shift VMOs and insurer bargaining power toward the largest, best-capitalised operator [S22].

Bear case

  1. Valuation already discounts recovery: ~36x underlying P/E and a share price above the average analyst target leave little margin for execution slippage [S18].

  2. UK drag persists: NHS commissioning cuts and wage inflation could stall Ramsay UK and keep Elysium near break-even returns (ROCE 3.4%), with further impairment risk [S2].

  3. Payor pushback: insurer payout ratios recovering toward 88% may prompt tougher future indexation, while down-tiering erodes mental health and maternity volumes [S3].

Key catalysts and monitorables (next 12 months)

  • Release of Demerger Booklet and independent expert's conclusion (Oct 2026); scheme vote and AGM (24 Nov 2026); implementation (Dec 2026) and initial ASX trading of Santé CDIs.

  • Investor Day (30 Nov 2026) — potential medium-term margin/ROCE targets for "new Ramsay".

  • 1H FY27 result (Feb 2027): Australian margin trajectory, National Capital integration, Elysium EBIT.

  • PHI contract renewals and indexation; APRA payout-ratio data.

  • NHS 2027/28 tariff and elective commissioning budgets.

  • Paul Ramsay Foundation sell-down cadence; any capital management (buyback/DRP reinstatement) post-demerger.

  • Healthscope ownership transfer to Calvary-led consortium (by 30 Nov 2026).

Concluding analyst verdict

Ramsay Health Care is mid-way through the most consequential reshaping since its 2014 entry into France. FY26 marked a genuine operational inflection: every region grew EBIT, the Australian franchise delivered 11.2% underlying EBIT growth with margin expansion, the Funding Group's free cash flow multiplied almost sevenfold, and leverage fell to 1.83x. Management's priorities — utilisation over greenfield, procurement and revenue-cycle discipline, indexation-linked payor contracts and portfolio pruning — are coherent, measurable and showing early returns, and the rebuilt executive team has credible operating pedigrees.

The proposed demerger of Ramsay Santé is strategically sound. Santé contributes almost 30% of EBIT but nothing to Ramsay's bottom line after interest and minorities, consumes management attention, inflates the tax rate and obscures the quality of the Australian business. Post-separation, Ramsay becomes a simpler, investment-grade, Australia-centric hospital operator with a mid-teens ROCE and a UK option.

The debate is valuation and durability. After a ~58% year-to-date rally, the shares trade around 36x underlying FY26 EPS (roughly 30x on the Funding Group perimeter), above average analyst targets, implicitly pricing several years of double-digit earnings growth. That outcome requires continued above-inflation PHI indexation, further utilisation gains, a successful Elysium turnaround in a contracting market and no renewed NHS shock — while labour costs remain the swing factor everywhere. Margins also remain below pre-COVID levels, so the recovery is far from complete, but the market is now paying for it.

Verdict: fundamentally improving, strategically well-positioned, but fully valued near term. The risk/reward is balanced; the November 2026 vote and the 30 November Investor Day are the next decisive tests. A constructive stance on business quality is warranted, with entry discipline on valuation — monitor 1H FY27 Australian margins and Elysium cash generation as the key confirmation signals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles and education

Natalie Davis

Managing Director and Group CEO; Chair of Ramsay Générale de Santé

Joined Oct 2024; CEO from 2 Dec 2024

MD Woolworths Supermarkets (130,000 staff, >A$46bn revenue); Chief Customer Transformation Officer and MD Woolworths NZ; 15 years McKinsey partner (ANZ/UK); MBA INSEAD; BCom/LLB (First Class Hons, University Medal), University of Sydney; former NED Quantium

Anthony Neilson

Group CFO / Group Executive Finance; Director of Ramsay Santé

From 24 Nov 2025

Santos: CFO (5 yrs) then Chief Commercial Officer (3+ yrs); CEO and CFO of Roc Oil; MBA AGSM (UNSW); Fellow CA ANZ

Stuart Winters

Chief Operating Officer, Australia

n.d. (appointed during FY26 executive rebuild)

Led Sodexo's US Healthcare and Senior Living businesses; CEO Sodexo UK and Ireland

Andrew Coombs

Chief Commercial Officer, Australia

Appointed ~Nov 2025

VP Commercial, HCA Healthcare UK; MD AXA Global Health; CEO AXA Global Protect; KPMG

Dr Brindan Suresh

Group Executive Health & Strategy

—

McKinsey Partner (health systems); NSW Health doctor; MBBS, LLB (Hons I), BA, University of Sydney

Dr John Doulis

Group Executive Technology & Digital

Appointed ~Nov 2025

VP and Distinguished Architect, HCA Healthcare digital transformation; CIO/Informatics leader, Vanderbilt University Medical Center; Monash medical graduate

Colleen Harris

Group Executive People

Since 2018

Senior HR roles at NAB, Federation Centres, MyState

Henrietta Rowe

Group Executive Legal & Company Secretariat; Director of Ramsay Santé

Since June 2019

Herbert Smith Freehills; Commonwealth Bank; LLB/BEc (Hons I), Sydney

Nick Costa

Managing Director, Ramsay UK

MD since Jan 2022

Ramsay UK COO for 4 years

Joe O'Connor

Managing Director/CEO, Elysium Healthcare

From Jan 2026

—

Pascal Roché

Managing Director (CEO), Ramsay Santé

Since 2011

Chairman, Ramsay Santé Corporate Foundation

Board of Directors

DirectorRoleAppointedNotes

David Thodey

Independent Non-Executive Chairman; chairs Governance Committee

Board Nov 2017; Chair since 2023

Chair of Xero; Chancellor, University of Sydney; former Telstra CEO

Natalie Davis

Managing Director and Group CEO

2 Dec 2024

Executive

Michael Siddle

Non-Executive Director (founding director)

Director since 1975

Chairman 2014–2023; retiring at end of 2026 AGM (24 Nov 2026)

Alison Deans

Non-Executive Director

—

Chair of Cochlear and Calix; technology/digital background

Karen Penrose

Non-Executive Director; chairs Audit Committee

—

30+ years finance, property, healthcare, resources; professional NED since 2014

Steven Sargent

Non-Executive Director; chairs Risk Management Committee

—

Multi-industry international experience incl. healthcare and energy

Helen Kurincic

Non-Executive Director

—

Chair of McMillan Shakespeare; healthcare operator background

Craig Drummond

Non-Executive Director

1 Jul 2025

Chair of Transurban, AFIC and The Ian Potter Foundation

Dr Tracey Batten

Incoming Non-Executive Director

From 1 Jan 2027

30+ years healthcare; NED Medibank (retiring Nov 2026) and Nanosonics

Dr Claudia Süssmuth Dyckerhoff

Former NED

Oct 2018 – 31 Aug 2026 (retired)

Risk Management Committee

James McMurdo

Former NED

2019 – Nov 2025 (retired)

Audit Committee

Directors' Remuneration

ItemDetail

CEO fixed remuneration (appointment terms)

A$1.8m per annum

CEO STI target

100% of fixed remuneration

CEO LTI

Annual grant up to 150% of fixed remuneration in performance rights

CEO FY25 total remuneration (partial year)

c.A$2.73m (37.9% salary) per data aggregator

CEO FY26 statutory remuneration

n.d. (FY26 Annual Report remuneration table not located during review)

Other KMP remuneration

—

2025 AGM remuneration report vote

Passed with 80.5% support (19.5% against — below the 25% "strike" threshold)

Major Shareholders

HolderStakeDate

Paul Ramsay Holdings Pty Ltd (Paul Ramsay Foundation)

16.4% (37,964,360 shares; reduced from 17.578%)

31 Jul 2026 / notice 8 Jul 2026

Orbis Investment Management

Purchased 4.41m shares Feb 2025; current % n.d.

Feb 2025

Australian Foundation Investment Company

Listed among top holders; % n.d.

—

BlackRock, Vanguard, State Street and other index funds

Present on register; current % n.d.

—

Top-10 institutional holders with percentages

n.d. in reviewed primary sources; historical aggregator data suggested top 25 holders own ~62%

—

Insider ownership — Natalie Davis

~0.02%

2025

Directors' on-market purchases (Sep 2024)

Thodey 2,475 shares; Kurincic 2,000; Penrose 1,225

Sep 2024

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnershipComparative scalePositioning vs Ramsay

Australia acute

Healthscope

In receivership since May 2025; remaining 31 hospitals to Calvary-led consortium

37 hospitals, 19,000+ staff, ~650,000 patients pa at receivership; revenue n.d.

Formerly #2; weakened, now being restructured into not-for-profit

Australia acute

Calvary Health Care

Not-for-profit (Catholic)

—

Consolidator of Healthscope assets; will become a larger rival

Australia acute

St Vincent's Health Australia

Not-for-profit

—

Large Catholic network; public and private

Australia acute

Epworth HealthCare, Cabrini, Mater, Healthe Care

Not-for-profit / private

—

Strong metropolitan positions (Melbourne, Brisbane)

Australia day surgery

Independent day hospital operators

Various

Day surgeries received ~4% of PHI benefits vs 85% for private hospitals (12 months to Mar 2026)

Lower-cost substitutes for simple procedures

UK acute

Spire Healthcare

LSE-listed

FY25 revenue £1,579.8m; adj. EBITDA £268.6m; ~30% of hospital revenue from NHS

Largest listed UK peer; less NHS-dependent than Ramsay UK; subject of 2026 takeover approach by Toscafund

UK acute

Circle Health Group, Nuffield Health, HCA Healthcare UK

Private / charity / US-listed parent

—

HCA dominant in London private; Circle/Nuffield national networks

UK mental health

Priory, Cygnet (UHS), Active Care Group

Private

—

Direct competitors to Elysium for NHS and local authority placements

France

Elsan

Private

~217 establishments, ~28,000 staff (company recruitment profile; not a primary filing)

#1/#2 French private hospital group alongside Ramsay Santé

France

Vivalto Santé, Almaviva Santé

Private

—

Regional consolidators

Nordics

Aleris, Praktikertjänst

Private / cooperative

—

Primary and specialist care competition

Peer Comparison FY2026

MetricRamsay Group FY26Ramsay Funding Group FY26Spire Healthcare FY25 (Dec YE)HealthscopeElsan

Revenue

A$18,690m

A$9,423m

£1,579.8m

——

Revenue growth

5.1% (4.2% cc)

4.9% (5.2% cc)

4.5%——

EBITDA margin

12.4% (reported)

13.2%

17.0% (adjusted)

——

Underlying/adjusted EBIT margin

6.2%8.8%

9.5% (adjusted)

——

R&D intensity

—————

Leverage

Consolidated net debt incl. leases/EBITDA 4.5x

1.83x (covenant)

2.0x net bank debt/EBITDA covenant

A$1.6bn debt at receivership

—

“—” = not publicly disclosed.

Company Snapshot

92,400

Employees

1964

Founded

St Leonards, Australia

Headquarters

SWOT Analysis

Strengths

  • Market leadership in Australia: Largest private operator; 70 facilities; 1.24m admissions FY26 [S2]
  • Australian earnings momentum: Underlying EBIT +11.2% FY26, 2H +15.9%, margin +30bps to 9.4% [S3]
  • Strong Funding Group balance sheet: Leverage 1.83x vs <2.5x target; Fitch BBB-; A$1,066m liquidity [S3]
  • Owned real estate: 44 owned Australian hospitals, A$808.6m EBITDAR [S3]
  • Improving capital returns: Funding Group ROCE 14.8% (+150bps); Australia ROCE 17.4% [S2]
  • Clinical quality and patient advocacy: Patient NPS 73.6 Australia, 89 UK; readmissions 44% below sector benchmark [S3]
  • Cash generation: Funding Group OCF +46% to A$869.1m; all Funding Group businesses FCF-positive [S2]

Weaknesses

  • Thin consolidated margins: Underlying EBIT margin 6.2% vs 6.9% FY22 [analysis of S2/S6]
  • Elysium under-earns: ROCE 3.4%; A$305m UK impairment FY25; revenue -4.2% cc FY26 [S2]
  • Ramsay Santé value drag: Underlying loss after tax attributable A$34.3m FY26; leverage 4.7x; Moody's B1 Negative [S2][S3]
  • High lease and interest burden: Consolidated finance costs A$608.4m vs EBIT A$1,105.4m [S2]
  • Labour intensity: Employee costs 57% of revenue; Elysium 80.5% [S2]
  • Weak consolidated FCF after leases: A$104m FY26 vs A$238m dividends paid [S2]
  • Digital lag: EHR programme slowed; FY25 digital capex guidance cut from A$70–80m to A$13–18m [S4]

Opportunities

  • Demerger re-rating: Funding Group underlying NPAT A$398.4m exceeds consolidated A$364.1m [S2]
  • Healthscope dislocation: Rival in receivership; Ramsay acquired National Capital (top-20 hospital) [S12][S22]
  • Theatre utilisation upside: Lowest-20 sites ~50% utilisation vs top-5 80–85%+ [S3]
  • Indexation reform: Four payor agreements linked to sector metrics; new multi-year insurer partnership [S3]
  • Growing insured base: 12.8m insured (+2.5% p.a.); payout ratio recovering toward 88% [S3]
  • Clinical trials and high-acuity niches: Trials +28%; 22 sites; cardiology/oncology/orthopaedics focus [S3]
  • Capacity in growth corridors: 11 theatres/cath labs opening FY27 (Hollywood, St George, Westmead) [S3]

Threats

  • NHS commissioning cuts: Ramsay UK NHS volumes -8.2% FY26 [S2]
  • Wage and statutory cost inflation: UK National Living Wage +6.7%/+4.1%; NI increase £4m (Ramsay UK) and £5.6m (Elysium) [S2]
  • Insurance down-tiering: Silver tier 38%, hurting mental health and maternity [S3]
  • Public contract repricing: Joondalup new funding mechanism -A$37m gross / -A$26m net [S2]
  • Industrial relations/legal: FWC ruling forced A$20.5m prior-period provision [S2]
  • Sector-wide financial stress: Healthscope collapse with >A$1.6bn debt shows fragility of the operator model [S22]
  • Climate commitments credibility: Net zero (Scope 1+2) target delayed from 2040 to 2050 [S1]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Group CFO Martyn Roberts departs; Mike Hirner acting [S15]Finance leadership gap during strategic review
8 May 2025New Ramsay–Bupa Australia agreement with out-of-hospital pilots [S21]Secures major payor; tests new care models
May 2025Craig Drummond appointed NED (effective 1 Jul 2025) [S16]Board renewal with healthcare/financial expertise
26 May 2025Healthscope (Australia's #2 private operator, 37 hospitals) enters receivership [S22]Competitor distress; acquisition opportunities; sector funding debate
30 Jun 2025Craig McNally completes transition and steps down as Santé Chair; Davis becomes Santé Chair [S25][S14b]Completes CEO handover
28 Aug 2025FY25 results: statutory NPAT A$24.0m (-91%); underlying EPS 125.3c; DPS flat 80c; DRP suspended; improved PHI indexation for FY25–26 [S7]Trough year; shares rose ~10% on day
Late 2025Paul Ramsay Holdings sells 585,000 shares at A$35.19 [S17]Start of foundation sell-down
17 Nov 2025Anthony Neilson named Group CFO; Andrew Coombs (CCO Australia) and Dr John Doulis (Technology & Digital) join [S15]New Group Executive complete
25 Nov 2025AGM and Q1 FY26 trading update: Australian revenue +6.5%, EBIT +5.8% vs consensus decline; Santé review options finalised [S20][S26]Positive earnings inflection signal
25 Nov 2025Remuneration report passes with 80.5%; James McMurdo retires [S26]Governance
23 Dec 2025Agreement to buy National Capital Private Hospital for A$251m [S12]First ACT asset; disciplined bolt-on
5 Jan 2026St Göran 8+4-year contract commences [S3]Nordic earnings uplift (+65.6% cc EBIT FY26)
Jan 2026Joe O'Connor commences as Elysium CEO [S2]Turnaround leadership
20 Feb 2026Proposal to demerge Ramsay Santé via in-specie distribution; SHA with Crédit Agricole to terminate 1 Oct 2026 [S9]Most significant structural change in a decade
26 Feb 20261H FY26: underlying EBIT +7.3%, underlying NPAT +8.1%, revenue A$9.3bn (+9.7%); interim DPS 42.5c (+6.3%); statutory NPAT A$160.7m vs A$104.9m loss [S19]Shares +10.4% on the day
Mar 2026Healthscope CEO change; receivers begin break-up [S22]Market structure shift
1H CY2026ACCC approves National Capital acquisition [S12b]Regulatory clearance
24 Jun / 22 Jul 2026Ramsay Santé launches and closes €1.75bn refinancing (€1.55bn TLB + €200m RCF at E+350bps; maturities extended to 2033; change-of-control drafted for demerger) [S10][S3]Removes key demerger financing risk
6–8 Jul 2026Paul Ramsay Holdings reduces holding from 17.578% to 16.447% [S17]Ongoing overhang
Jul 2026Attadale Rehabilitation Hospital site sold [S3]Capital recycling
12 Aug 2026Warringal Private Hospital emergency department opens; Cleveland Surgical Centre opens (Aug) [S3]Capacity in growth corridors
26 Aug 2026Ramsay Santé FY26 (June YE): EBITDA €637.7m (+2.6%), margin 11.9%; net loss group share €48.3m [S28]Standalone Santé profile ahead of demerger
27 Aug 2026FY26 results: underlying NPAT +22.9% cc; final DPS 48.5c (+21.3%); Funding Group leverage 1.83x; net-zero reset to 2050 [S1][S18]Shares +13.7% (close A$50.06); ~A$1.2bn value added
31 Aug 2026Dr Claudia Süssmuth Dyckerhoff retires from Board [S16]Board renewal
1 Sep 2026National Capital acquisition completes [S13]Integration begins; EPS-accretive guidance
~2 Sep 2026Ramsay UK extends long-term partnership with VitalityHealth [S21]Supports private-pay strategy
10 Sep 2026Shares reach multi-year high A$54.11, ~57% YTD [S18]Re-rating as turnaround story
17 Sep 2026Ramsay Santé Capital Markets Day unveils "Connecting Care 2030"; Crédit Agricole reaffirms long-term commitment [S11]Equity story for Santé post-demerger
24 Sep 2026Founding director Michael Siddle to retire at 2026 AGM; Dr Tracey Batten appointed from 1 Jan 2027; FY26 Corporate Governance Statement released [S16]End of founding-era board link
30 Sep 2026CARES record date; A$3.3608 per CARES dividend payable 20 Oct 2026 [S18]Hybrid servicing
Oct 2026AGM notice for 24 Nov 2026 (AGM, then General and Scheme Meetings); Demerger Booklet expected in October (not located as at 14 Oct 2026) [S30][S8]Key catalyst ahead
7 Oct 2026Share price A$54.55 [S18]Near highs
Oct–Nov 2026Calvary-led consortium confirmed as buyer of remaining Healthscope hospitals (completion expected by 30 Nov 2026) [S22]Competitor reconstituted as not-for-profit

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

10 charts
Income Statement: Revenue & Gross Profit: Total revenue and other income less interest income rose from AUD 13,740 Mn in FY2022 to AUD 18,690.3 Mn in FY2026.
Ramsay Health Care Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue and other income less interest income13,74015,329.316,772.117,779.318,690.3
Revenue from contracts with customers—14,963.916,660.217,673.818,577.8
Gross profit proxy: total revenue less medical consumables—12,021.513,065.713,849.514,578.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Ramsay FY26 ASX results announcement, 27 Aug 2026 (announcements.asx.com.au)
  2. S2Ramsay FY26 Appendix 4E and Full Year Results (incl. OFR and financial statements), 27 Aug 2026 (announcements.asx.com.au)
  3. S3Ramsay FY26 Results Presentation and speech, 27 Aug 2026 (announcements.asx.com.au)
  4. S4Ramsay FY24 Appendix 4E and Full Year Results, 30 Aug 2024 (prod.ramsayhealth.com)
  5. S5Ramsay FY23 ASX results announcement, 24 Aug 2023 (announcements.asx.com.au)
  6. S5bRamsay 1H FY24 results presentation (prod.ramsayhealth.com)
  7. S6Ramsay FY22 ASX results announcement, 26 Aug 2022 (asx.com.au)
  8. S7FY25 results: Appendix 4E; InvestSMART summaries; FY25 transcript · investsmart.com.au
  9. S8Ramsay demerger investor page (ramsayhealth.com)
  10. S9Update on Strategic Review of Ramsay Santé, 20 Feb 2026 (announcements.asx.com.au)
  11. S9bRamsay Santé press release, 20 Feb 2026 (finance.yahoo.com)
  12. S10Ramsay Santé refinancing press release, 22 Jul 2026 (ramsaysante.eu)
  13. S11Ramsay Santé Capital Markets Day, 17 Sep 2026 · ramsaysante.fr
  14. S11bRamsay Santé note on Ramsay financial adviser appointment, 27 Feb 2025 (globenewswire.com)
  15. S12Ramsay acquires National Capital Private Hospital, 23 Dec 2025 (announcements.asx.com.au)
  16. S12bCapital Brief / Region Canberra coverage of National Capital (beds, ACCC) · region.com.au
  17. S13Ramsay completes acquisition of National Capital, 1 Sep 2026 (announcements.asx.com.au)
  18. S14Ramsay Board and management page (ramsayhealth.com)
  19. S14bRamsay Australia leadership page (ramsayhealth.com.au)
  20. S15Appointment of Group CFO, 17 Nov 2025; Capital Brief coverage · capitalbrief.com
  21. S16Board changes 24 Sep 2026; Corporate Governance Statement coverage; Süssmuth Dyckerhoff retirement; McMurdo retirement · kalkinemedia.com · tipranks.com
  22. S17Paul Ramsay Holdings change in substantial holding (FilingReader, 8 Jul 2026) (filingreader.com)
  23. S18Share price and market data: Kalkine (7 Oct 2026), Motley Fool (10 Sep 2026), Stocklight (27–29 Aug 2026), Simply Wall St (CARES dividend), MarketMatters (Aug 2023) · fool.com.au · stocklight.com · simplywall.st · marketmatters.com.au
  24. S191H FY26 results coverage (InvestSMART; TipRanks) · tipranks.com
  25. S20Q1 FY26 trading update (Capital Brief) (capitalbrief.com)
  26. S21Payor partnerships: Bupa Australia (May 2025; 2022 HPPA), VitalityHealth (LaingBuisson, Sep 2026), Bupa UK · laingbuissonnews.com · ramsayhealth.co.uk
  27. S22Healthscope receivership and sale (Urban Developer; Wikipedia; Manning River Times) · en.wikipedia.org · manningrivertimes.com.au
  28. S23Spire Healthcare FY25 results, 5 Mar 2026 (investors.spirehealthcare.com)
  29. S24APRA quarterly private health insurance statistics (Mar and Jun 2026) · apra.gov.au
  30. S25CEO transition announcement (Jul 2024) and pay terms (The Nightly) · thenightly.com.au
  31. S26Australian Shareholders' Association 2025 voting intentions and AGM report · australianshareholders.com.au
  32. S27KKR consortium proposal coverage (Apr 2022) (theurbandeveloper.com)
  33. S28Ramsay Santé FY26 (June) results (Zonebourse) (bourse.fortuneo.fr)
  34. S29Simply Wall St management and ownership data · simplywall.st
  35. S29bMotley Fool RHC director profiles (Morningstar data) (fool.com.au)
  36. S302026 AGM and demerger meeting notice (Boardroom; Globe and Mail/TipRanks) · theglobeandmail.com
  37. S31ESG rating coverage (Sustainalytics; KnowESG) · knowesg.com
  38. S32Elsan company profile (Indeed — secondary, low-reliability) (fr.indeed.com)
  39. S33InvestSMART RHC price history tables (investsmart.com.au)
  40. S34Consensus and broker data (MarketScreener; FNArena; Capital Brief FY24) · fnarena.com · capitalbrief.com

figures dependent on them are marked n.d. Aggregator data (Simply Wall St, MarketScreener, TipRanks) are used only where primary disclosure was unavailable and are identified as such.*

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.